Amikacin Penetration Into the Cerebrospinal Fluid

Rambam Health Care Campus

Overview

The limited available data precludes establishing an antibiotic regimen in patients suffering from bacterial meningitis after head trauma, or spontaneous bleeding Understanding the disposition of Amikacin administered intrathecally will enable to propose rational treatment of these patients.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

Gram Negative Meningitis Post Traumatic Bacterial Meningitis

Interventions

Systemic and Intra-Thecal Amikacin TherapyDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Culture proved bacterial meningitis where the prescribed therapy includes the use of systemic and intraventricular amikacin therapy. 2. The included patient should have an intraventricular catheter placed for intraventricular pressure measurement and admitted to an intensive care unit. 3. Blood creatinine concentration up to 1.49 mg/dL measured at the inclusion day. Exclusion Criteria: 1. Patients or legal guardians who refuse to participate in the study. 2. Known allergy to amikacin. 3. Blood creatinine concentration of 1.5 mg/dL or higher. 4. Subjects without intraventricular catheter who will need repeated lumbar punctures for CSF amikacin determinations. 5. Patients suffering from known chronic liver disease.

Locations (1)

Rambam Health Care Campus

Haifa, Israel

Outcomes

Primary Outcomes

Bactericidal effect on the causative bacteria

Blood and CSF AUC/MIC relationship

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.